Business Description

Evotec SE (Evotec) is a provider of drug discovery and development solutions. The company works in partnership with pharmaceutical companies, small and large biotechnology companies, patient advocacy groups and academic institutions for the discovery and development of pharmaceutical products. It offers solutions ranging from early target identification to manufacturing of compounds and commercial products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

R&D Overview

The company’s R&D focuses on developing drug discovery programs through its in-house R&D capabilities, in partnership with pharmaceutical companies, small and large biotechnology companies, patient advocacy groups and academic institutions. Its R&D encompasses therapy areas including immunology, fibrosis, gynaecology, respiratory, neurology, oncology, kidney, pain, inflammation and rare diseases. As of December 31, 2021, Evotec had over 60 patent families and pipeline of about 100 partnered projects and 20 in-house projects under various stages of development. The major in-house and partnered projects under development include EVT201 in Phase III for insomnia; eliapixant in partnership with Bayer in Phase II clinical trials indicated for the treatment of chronic cough, overactive bladder, neuropathic pain and endometriosis; CT7001 in partnership with Carrick in Phase II for oncology; and EVT894 in partnership with Sanofi in Phase I for chikungunya. The company also has partnership with companies including Novo Nordics, Chinook, Conba Pharmaceutical, Bristol Myers Squibb and JinXing, among others. In FY2021, the company spent EUR72.2 million on its R&D, which as a percentage of revenue stood at 11.7%.

Business Segments

Overview

Offers standalone or integrated drug discovery and development solutions for customer-tailored drugs protected by the partners' intellectual property. It offers these solutions on a typical fee-for-service basis or through a variety of commercial structures including milestones, research fees and royalties. Offers drug discovery services including target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics (DMPK), absorption, distribution, metabolism, excretion and toxicity (ADME-Tox), in vitro biology and pharmacology services; integrated chemistry, manufacturing and control solutions such as API screening, route scouting, pre-clinical formulation, drug product formulation prototyping and development, clinical manufacturing, analytical development and quality control services. Provides solutions to design and manufacture biologics using its J. Design, J. Discovery, J. MD, JP3 and J. POD technologies. It offers gene therapy development services through Evotec GT, a gene therapy site in Austria. Offers its solutions in major therapy areas including immunology, neuroscience, diabetes, oncology, inflammation, pain, and anti-infectives.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Overview

Conducts drug discovery programs and develops its assets through academic collaborations. Uses its proprietary technology platforms to develop new drug discovery projects, assets and platforms, internally or through collaborations. It also builds translational (BRIDGE) partnerships with academia and selectively participates in high-potential ventures through strategic investments and company formations. Offers induced pluripotent stem cells (IPSC), a drug discovery platform for phenotypic screening to identify new mechanisms of disease.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Subscribe for access to business segment analysis Subscribe for access to business segment analysis Get Started



Geographical Segments

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Get started with Company Analytics for access to geographical segment data Get started with Company Analytics for access to geographical segment data Learn More
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer